Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2015;2015:146-51. doi: 10.1182/asheducation-2015.1.146.

Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn.

Author information

1
Seattle Children's Hospital, Seattle, WA; University of Washington, Seattle, WA; and Bloodworks NW, Seattle, WA.
2
Seattle Children's Hospital, Seattle, WA; University of Washington, Seattle, WA; and.

Abstract

Hemolytic disease of the fetus and newborn (HDFN) affects 3/100 000 to 80/100 000 patients per year. It is due to maternal blood group antibodies that cause fetal red cell destruction and in some cases, marrow suppression. This process leads to fetal anemia, and in severe cases can progress to edema, ascites, heart failure, and death. Infants affected with HDFN can have hyperbilirubinemia in the acute phase and hyporegenerative anemia for weeks to months after birth. The diagnosis and management of pregnant women with HDFN is based on laboratory and radiographic monitoring. Fetuses with marked anemia may require intervention with intrauterine transfusion. HDFN due to RhD can be prevented by RhIg administration. Prevention for other causal blood group specificities is less studied.

PMID:
26637714
DOI:
10.1182/asheducation-2015.1.146
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center